BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Richard Lindstrom Joins Board of Directors at Ocular Therapeutix, Inc.


11/6/2012 9:11:42 AM

BEDFORD, Mass., Nov. 5, 2012 /PRNewswire/ -- Ocular Therapeutix announced today the appointment of internationally acclaimed ophthalmologist, Richard Lindstrom, M.D., to the company's Board of Directors.

Dr. Lindstrom is a board-certified surgeon and recognized leader in ophthalmic pharmaceuticals and cataract, corneal, and refractive surgery. He is the founder and an attending surgeon of Minnesota Eye Consultants, Adjunct Professor Emeritus at the University of Minnesota Department of Ophthalmology, and advisor to numerous ophthalmic companies throughout the world. He holds over 30 patents in ophthalmology, and has been at the forefront of the industry's evolutionary changes throughout his career.

"We are incredibly fortunate to have Dr. Lindstrom join our Board of Directors," stated Amar Sawhney, President and CEO of Ocular Therapeutix, Inc. "As one of the top thought leaders in the industry, Dr. Lindstrom's input and guidance will be invaluable as we advance our sustained release drugs through clinical trials."

Ocular Therapeutix's sustained release drug technology encapsulates proven and approved drugs within the company's proprietary polyethylene glycol (PEG) hydrogel and releases them in a sustained fashion over a predetermined period of time.

"Ocular Therapeutix's sustained release technology is an exciting prospect for the world of ophthalmology," stated Richard Lindstrom, MD. "These drugs have the potential to significantly advance the ophthalmic pharmaceutical industry by eliminating patient compliance issues and putting drug dosing in the hands of the physician."

About Ocular Therapeutix, Inc.:

Founded in November 2006, Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. Ocular Therapeutix is focusing on development of drug-eluting intracanalicular plugs for treatment of glaucoma and post-operative pain and inflammation, injectable depots for back-of-the-eye diseases, and an ocular sealant.

SOURCE Ocular Therapeutix, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES